Anterogen Co Ltd

Anterogen maintains a strong liquidity position with a current ratio of 78.12, indicating that its current assets significantly exceed its current liabilities. The company holds KRW 1.58 billion in cash and equivalents, and it has no long-term debt, which supports its liquidity profile. The price-to-book ratio of 3.5 and price-to-tangible-book ratio of 3.5 suggest that the company is trading at a premium relative to its book value, which may reflect investor expectations of future growth. The company's profitability metrics are currently negative, with a return on equity (ROE) of -1.57% and a return on assets (ROA) of -1.56%. These figures indicate that Anterogen is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating loss of KRW 243.3 billion and net loss of KRW 137.4 billion further underscore the company's current financial challenges. Anterogen's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic breakdown provided. This lack of diversification may expose the company to higher risk if demand for its products declines in its primary market. The company's revenue of KRW 7.54 billion in the latest period reflects a relatively small scale of operations compared to industry peers. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. However, the operating cash flow of -KRW 1.02 billion and free cash flow of -KRW 1.05 billion indicate that the company is not generating positive cash from operations, which could limit its ability to fund future growth initiatives without external financing. The risk assessment indicates that Anterogen faces low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is currently debt-free, and its equity base is substantial at KRW 87.45 billion. However, the negative operating and net income may necessitate future financing, which could lead to dilution if new shares are issued. Recent events include the company's continued focus on regenerative medicine and cell therapy development, as outlined in its business strategy. No significant regulatory or legal issues were disclosed in the latest filings, and the company has not issued any new shares in the recent period.